Alicia Grande - Aug 17, 2021 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
VP, Treasurer and CFO
Signature
/s/ Alicia Grande
Stock symbol
CPRX
Transactions as of
Aug 17, 2021
Transactions value $
-$110,379
Form type
4
Date filed
8/19/2021, 05:07 PM
Next filing
Dec 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $312K +100K +24.54% $3.12* 507K Aug 17, 2021 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$567K -100K -19.71% $5.67 407K Aug 17, 2021 Direct F1, F3
transaction CPRX Common stock, par value $0.001 per share Options Exercise $218K +70K +17.18% $3.12* 477K Aug 18, 2021 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$73.9K -13K -2.72% $5.68 464K Aug 18, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -100K -6.71% $0.00 1.39M Aug 17, 2021 Common Stock 100K $3.12 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -70K -5.03% $0.00 1.32M Aug 18, 2021 Common Stock 70K $3.12 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold in various lots from $5.62 to $5.725 per share. The listed sale price represents a weighted average price for the shares sold.
F2 Shares were sold in various lots from $5.65 to $5.785 per share. The listed sale price represents a weighted average price for the shares sold.
F3 Shares were sold to cover exercise price of options and tax withholding requirements.
F4 Options vested in three annual tranches beginning on August 28, 2015.